Search Results - "BACHMANN, K. A."

Refine Results
  1. 1

    Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise by Bachmann, K A

    Published in Current drug metabolism (01-01-2006)
    “…Strategies and standards for predicting the likelihood of pharmacokinetically significant inhibitory drug-drug interactions for drug development purposes which…”
    Get more information
    Journal Article
  2. 2

    In situ ToF-SIMS monitoring of SOFC cathodes – A case study of La0.74Sr0.17Mn1.01O2.9 model electrodes by Rohnke, M., Schaepe, K., Bachmann, A.-K., Laenger, M., Janek, J.

    Published in Applied surface science (15-11-2017)
    “…[Display omitted] •Polarisation experiments of structurally well-defined SOFC thin film model electrodes.•Electrode surface composition changes reversibly with…”
    Get full text
    Journal Article
  3. 3

    The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions by Bachmann, K A, Ghosh, R

    Published in Current drug metabolism (01-09-2001)
    “…With the dramatic change underway in the process of drug discovery and development it has become increasingly important to define, both qualitatively and…”
    Get more information
    Journal Article
  4. 4
  5. 5

    Differential kinetics of phenytoin in elderly patients by BACHMANN, K. A, BELLOTO, R. J

    Published in Drugs & aging (01-09-1999)
    “…The elderly have a relatively high risk of developing adverse drug reactions. Phenytoin continues to be a preferred drug for treating generalised tonic-clonic…”
    Get full text
    Journal Article
  6. 6

    Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo by Bachmann, K A, Jauregui, L

    Published in Xenobiotica (1993)
    “…1. Single sample clearance estimates (CL/F) of orally administered ethosuximide were obtained in four groups of healthy adult subjects. One group was treated…”
    Get more information
    Journal Article
  7. 7

    Lack of Pharmacokinetic Interaction between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients by Schwartz, Jules I., Agrawal, Nancy G. B., Wong, Peggy H., Bachmann, Kenneth A., Porras, Arturo G., Miller, Jutta L., Ebel, David L., Sack, Marshall R., Holmes, Gregory B., Redfern, Jan S., Gertz, Barry J.

    Published in Journal of clinical pharmacology (01-10-2001)
    “…Rofecoxib is a highly selective and potent inhibitor of cyclooxgenase‐2 (COX‐2). Methotrexate is a disease‐modifying agent with a narrow therapeutic index…”
    Get full text
    Journal Article
  8. 8

    Influence of Some Novel N-Substituted Azoles and Pyridines on Rat Hepatic CYP3A Activity by Slama, James T., Hancock, Julie L., Rho, Taikyun, Sambucetti, Lidia, Bachmann, Kenneth A.

    Published in Biochemical pharmacology (01-06-1998)
    “…A series of N-substituted heteroaromatic compounds structurally related to clotrimazole was synthesized, and the effects of these compounds on ethosuximide…”
    Get full text
    Journal Article
  9. 9

    Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity by BACHMANN, K. A., SULLIVAN, T. J., JAUREGUI, L., REESE, J. H., MILLER, K., LEVINE, L.

    Published in British journal of clinical pharmacology (01-10-1993)
    “…The effects of omeprazole (40 mg orally per day) and nizatidine (300 mg orally per day) on the disposition of phenytoin (4.5 mg kg−1 p.o. single dose) were…”
    Get full text
    Journal Article
  10. 10

    The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo by Loch, J M, Potter, J, Bachmann, K A

    Published in Pharmacology (01-03-1995)
    “…The objective of this study was to identify which anesthetics when used acutely will affect cytochrome P450 (CYP) activity in male Sprague-Dawley rats in vivo…”
    Get more information
    Journal Article
  11. 11

    Ethosuximide is Primarily Metabolized by CYP3A when Incubated with Isolated Rat Liver Microsomes by SARVER, J. G, BACHMANN, K. A, ZHU, D, KLIS, W. A

    Published in Drug metabolism and disposition (01-01-1998)
    “…The cytochrome P450 (CYP) subfamily responsible for ethosuximide metabolism was investigated by HPLC assay of ethosuximide incubations with isolated rat liver…”
    Get full text
    Journal Article
  12. 12

    The use of single-sample clearance estimates to probe hepatic drug metabolism in rats. IV. A model for possible application to phenotyping xenobiotic influences on human drug metabolism by Bachmann, K A

    Published in Xenobiotica (1989)
    “…1. Conditions were examined under which estimates of drug clearance made from a single measurement of plasma concentration effectively represented multi-sample…”
    Get more information
    Journal Article
  13. 13

    Predicting Inhibitory Drug-Drug Interactions and Evaluating Drug Interaction Reports Using Inhibition Constants by Bachmann, Kenneth A, Lewis, Jeffrey D

    Published in The Annals of pharmacotherapy (01-06-2005)
    “…OBJECTIVE: To review the use of inhibitory constants (Ki) determined from in vitro experiments in the prediction of the significance of inhibitory drug—drug…”
    Get full text
    Journal Article
  14. 14

    Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients by SCHWARTZ, J. I, JAUREGUI, L. E, BACHMANN, K. A, MARTIN, M. E, REITBERG, D. P

    Published in Antimicrobial Agents and Chemotherapy (01-05-1988)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  15. 15

    The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of phenobarbitone on human hepatic drug metabolism by Bachmann, K A, Nunlee, M, Martin, M, Jaregui, L

    Published in Xenobiotica (1991)
    “…1. Single sample clearance estimates, CL, were calculated for seven drugs employed as probes of human hepatic drug-metabolizing enzymes. Clearance estimates…”
    Get more information
    Journal Article
  16. 16

    The effects of cobalt chloride, SKF-525A, and N-(3,5-dichlorophenyl)succinimide on in vivo hepatic mixed function oxidase activity as determined by single-sample plasma clearances by Bachmann, K A, Madhira, M S, Rankin, G O

    Published in Xenobiotica (01-01-1992)
    “…1. Four drugs--antipyrine, theophylline, quinidine, and ethosuximide--were used as probes of in vivo hepatic mixed function oxidase (MFO) activity. Functional…”
    Get more information
    Journal Article
  17. 17

    Dispositional and pharmacodynamic characteristics of brodifacoum in warfarin-sensitive rats by Bachmann, K A, Sullivan, T J

    Published in Pharmacology (01-01-1983)
    “…A dose-response curve for the hypoprothrombinemic effect of brodifacoum 3-[-3(4'-bromobiphenyl-4-yl) 1,2,3,4-tetrahydronaphth-1-yl] -4-hydroxycoumarin, was…”
    Get more information
    Journal Article
  18. 18

    Exercise training does not alter cytochrome P-450 content and microsomal metabolism by Michaud, T J, Bachmann, K A, Andres, F F, Flynn, M G, Sherman, G P, Rodriguez-Zayas, J

    “…The purpose of this investigation was to determine whether increased endurance exercise capacity alters total hepatic cytochrome P-450 content and cytochrome…”
    Get more information
    Journal Article
  19. 19

    Accuracy of two equations in determining normalized phenytoin concentrations by Mauro, L S, Mauro, V F, Bachmann, K A, Higgins, J T

    Published in DICP (Cincinnati, Ohio) (01-01-1989)
    “…The accuracy of two equations in normalizing total phenytoin concentrations in the presence of renal failure or hypoalbuminemia was evaluated in 11 renal…”
    Get more information
    Journal Article
  20. 20

    An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats by Liu, D, Bachmann, K A

    “…17 beta-Estradiol (E2) has long been known for protecting against coronary heart disease by lowering cholesterol levels in premenopausal women. A recent study…”
    Get more information
    Journal Article